Monitoring Haematocrit in Paediatric Patients Receiving Testosterone Therapy in Arab Countries.
arab
asped
erythrocytosis
haematocrit
monitoring
testosterone
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
accepted:
31
08
2021
entrez:
14
10
2021
pubmed:
15
10
2021
medline:
15
10
2021
Statut:
epublish
Résumé
Objectives Testosterone is the main agent used to induce puberty in boys in Arab countries. It is recommended to monitor haematocrit before and during androgen replacement. However, data from single centre studies indicated that this recommendation is rarely practiced by paediatricians compared to adult physicians. The aim of this study is to evaluate the monitoring of haematocrit of patients on Testosterone therapy by paediatric endocrinologists practicing in Arab countries. Methods A cross-sectional study using an online survey that was sent to all members of the Arab Society for Paediatric Endocrinology and Diabetes (ASPED), who they practice in all Arab countries. The study was carried out between July and October 2019. Ethical approval was granted by ASPED council in May 2019 (MRE2019-02Q). Results One hundred four physicians responded to the survey from 17 countries. 81/104 (77.8%) answered the question about Testosterone monitoring (42 paediatric endocrinologists, 11 general paediatrician consultants with interest in endocrine, 16 specialists, four fellows and eight residents). Of the 81 responders 18 clinicians (22.2%) thought of monitoring the haematocrit; 15 (18.5%) thought no laboratory monitoring is needed at all. Conclusion The survey indicated that most paediatric endocrinologists in Arab countries do not monitor haematocrit in patients on testosterone replacement and majority are not aware that secondary erythrocytosis can result from androgen therapy. Raising the awareness on monitoring haematocrit during androgen replacement therapy is needed especially when reaching the adult dose.
Identifiants
pubmed: 34646669
doi: 10.7759/cureus.17618
pmc: PMC8483389
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e17618Informations de copyright
Copyright © 2021, Alsaffar et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Horm Res Paediatr. 2018;90(2):123-127
pubmed: 30021202
J Pediatr Endocrinol Metab. 2015 May;28(5-6):635-40
pubmed: 25324443
J Clin Endocrinol Metab. 1999 Oct;84(10):3469-78
pubmed: 10522982
Intern Med J. 2021 Jun;51(6):873-878
pubmed: 32237098
Br J Clin Pharmacol. 2013 Jan;75(1):260-70
pubmed: 22574772
Aging Male. 2019 Jun;22(2):141-149
pubmed: 29921150
J Laryngol Otol. 2016 Mar;130(3):309-13
pubmed: 26653249
Intern Med J. 2016 Apr;46(4):497-9
pubmed: 27062206
CMAJ. 2017 Oct 16;189(41):E1286-E1288
pubmed: 29038321
Expert Opin Pharmacother. 2010 Jun;11(9):1529-40
pubmed: 20482304
J Urol. 2019 Mar;201(3):587-594
pubmed: 30296416
Am J Clin Pathol. 2020 Jun 8;154(1):33-37
pubmed: 32134468
Med J Aust. 2000 Mar 6;172(5):220-4
pubmed: 10776394
Asian J Androl. 2018 Mar-Apr;20(2):195-199
pubmed: 29205178
J Sex Med. 2020 Jul;17(7):1297-1303
pubmed: 32307242
Int J Impot Res. 2007 Jan-Feb;19(1):2-24
pubmed: 16193074
Retin Cases Brief Rep. 2019 Aug 28;:
pubmed: 31464822
Urology. 2019 Feb;124:127-130
pubmed: 30447269
Horm Res Paediatr. 2019;92(4):215-228
pubmed: 31851967
Fertil Steril. 1999 Feb;71(2):244-8
pubmed: 9988392
Sex Med Rev. 2018 Jan;6(1):77-85
pubmed: 28526632
N Engl J Med. 2004 Jan 29;350(5):482-92
pubmed: 14749457
J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744
pubmed: 29562364
Med J Aust. 2016 Sep 5;205(5):228-31
pubmed: 27581270
J Endocr Soc. 2020 Oct 30;5(1):bvaa161
pubmed: 33294762
Curr Med Res Opin. 2016;32(2):271-2
pubmed: 26551968
Rev Urol. 2004;6 Suppl 6:S3-8
pubmed: 16985909
Fertil Steril. 2012 Oct;98(4):836-42
pubmed: 22763096
J Pediatr Endocrinol Metab. 2020 Sep 25;33(9):1197-1202
pubmed: 32809957